Natera director Jonathan Sheena sells $123,548 in shares By Investing.com

Jonathan Sheena, a director and co-founder at Natera, Inc. (), sold shares totaling $123,548 over two separate transactions in late July 2026. The sales occurred at prices ranging from $254.0696 to $260.4908.

On July 27, 2026, Sheena disposed of 288 shares of common stock at a price of $260.4908 per share. The following day, July 28, 2026, an additional 191 shares were sold at $254.0696 per share. These transactions were undertaken to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs) and were conducted under a Rule 10b5-1 trading plan.

Following these transactions, Jonathan Sheena directly holds 245,723 shares of Natera common stock. Additionally, 18,032 shares are held indirectly by the Caraluna 1 Trust and another 18,032 shares by the Caraluna 2 Trust for the benefit of their beneficiaries. Sheena disclaims beneficial ownership over these indirectly held securities.The insider sale comes as Natera’s stock has delivered an impressive 80% return over the past year, though InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value. Trading at $253.82, the company commands a market cap of $36.35 billion. According to InvestingPro Tips, the stock exhibits high volatility—one of several key insights available to subscribers. For deeper analysis, investors can access Natera’s comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US equities.

In other recent news, Natera Inc. announced that its Signatera test has achieved certification under the European Union’s In Vitro Diagnostic Regulation as a Class C device. This certification encompasses the entire Signatera platform, including the assay, specimen collection kit, and software. Additionally, Natera published data in JAMA Oncology, demonstrating the effectiveness of its Signatera molecular residual disease test in predicting chemotherapy benefits for patients with resected colorectal liver metastases. The study, which involved 298 patients, was presented at the European Society for Medical Oncology Gastrointestinal Congress. In a strategic move, Natera has partnered with Aveta Biomics for a Phase 3 clinical trial to evaluate APG-157 in head and neck cancer patients, utilizing the Signatera test to monitor disease and treatment responses. Furthermore, Bernstein SocGen Group has resumed coverage of Natera with an outperform rating, noting the company’s potential for increased volumes and reimbursement in minimal residual disease testing. Japan is highlighted as a key market, with anticipated PMDA reimbursement and a commercial launch expected by year-end. Meanwhile, TD Cowen reported that Natera was among the companies with significant increases in short interest in the life sciences sector as of mid-July.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.